RE: The patent Cliff for big Pharma31 Dec 2023 09:21
There are various ways to extend the revenue from branded drugs by patenting new formulations (added active agents, enteric coating, slow release, controlled release, etc), new indications, new manufacturing processes. The original patent covering the active agent (the expiry of which is the main part of the patent cliff) would probably include a general catchall with wording "and prodrugs thereof." However when that patent expires, that protection goes also, which could explain why Bachovchin went after doxorubicin as there are no ptent issues there (lots of dose- and hence efficacy-limiting side effects though). For patents due to expire, the active agent should be fair game for any company to exploit in prodrug form.